Upperton Pharma Solutions Capacity Update January 2025: Small Molecule

Upperton, a UK-based CDMO, specializes in the development and manufacturing of oral solid, nasal, and pulmonary drug products, offering comprehensive services from pre-clinical development through late-stage manufacturing. With a science-driven approach and a focus on flexibility and precision, Upperton is dedicated to delivering unparalleled project outcomes for its clients.

Join Chief Technical Officer Ian Lafferty to explore Upperton’s expertise, project delivery approach, and advanced technologies. Gain insight into the capabilities of our award-winning 50,000 sq. ft. development and manufacturing facility, Trent Gateway, which features 10 state-of-the-art GMP manufacturing suites integrated with cutting-edge R&D and QC laboratories. Our team of subject matter experts, supported by executive leadership oversight on every project, ensures efficient and seamless delivery of high-quality drug products.

In this presentation, discover why Upperton is your integrated CDMO partner of choice for oral, nasal, and pulmonary dosage forms, committed to transforming ideas into exceptional pharmaceutical products.